荣昌生物 (688331.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.9x

Market Cap

CNY 65.72B

MomentumView details →

1D Return

−7.24%

YTD Return

—

RSI (14)

50.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.9x

Market Cap

CNY 65.72B

RSI (14)

50.0

MomentumView details →

1D Return

−7.24%

YTD Return

—

ProfitabilityView details →

Gross Margin

86.91%

Net Margin

38.20%

EBITDA Margin

29.15%

ROE (TTM)

32.88%

ROA (TTM)

17.54%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+76.81%

EPS YoY

+191.52%

FCF YoY

+103.97%

Revenue CAGR 3Y

+61.48%

EPS CAGR 3Y

+147.25%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 7.74

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

91.46%

Capital & dividendView details →

Debt/Equity

0.46x

Current Ratio

1.58x

Quick Ratio

1.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

3.38B

Net Income (TTM)

1.29B

Op. CF (TTM)

252.59M

Next earningsNov 4, 2026 →

Latest newsMore news →

China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.4d ago

RemeGen Co., Ltd. announced its 2026 interim results, reporting a net profit of 4.662 billion yuan, turning from a loss in the prior year.11d ago

Similar companies

argenx SEARGX Genscript Biotech Corporation01548.HK Encell Co. Ltd.456070.KQ Moderna, Inc.MRNA Amicogen, Inc.092040.KQ Pharmaron Beijing Co., Ltd.03759.HK Find similar companies →

Latest newsMore news →

China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.4d ago RemeGen Co., Ltd. announced its 2026 interim results, reporting a net profit of 4.662 billion yuan, turning from a loss in the prior year.11d ago RemeGen forecast first-half 2026 revenue of 5.85 billion yuan.17d ago